PANG Dan-mei, WEN Ling-zhu. Neoadjuvant Carboplatin in Patients with Triple Negative Early Breast Cancer Can Improve The Pathological Complete Response Rate[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 150-152. DOI: 10.12019/j.issn.1671-5144.2017.03.008
|
Citation:
|
PANG Dan-mei, WEN Ling-zhu. Neoadjuvant Carboplatin in Patients with Triple Negative Early Breast Cancer Can Improve The Pathological Complete Response Rate[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 150-152. DOI: 10.12019/j.issn.1671-5144.2017.03.008
|
PANG Dan-mei, WEN Ling-zhu. Neoadjuvant Carboplatin in Patients with Triple Negative Early Breast Cancer Can Improve The Pathological Complete Response Rate[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 150-152. DOI: 10.12019/j.issn.1671-5144.2017.03.008
|
Citation:
|
PANG Dan-mei, WEN Ling-zhu. Neoadjuvant Carboplatin in Patients with Triple Negative Early Breast Cancer Can Improve The Pathological Complete Response Rate[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 150-152. DOI: 10.12019/j.issn.1671-5144.2017.03.008
|
DownLoad: